Literature DB >> 9593270

Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation.

W Piacibello1, F Sanavio, L Garetto, A Severino, A Dané, L Gammaitoni, M Aglietta.   

Abstract

Cord blood (CB) is an attractive alternative to bone marrow or peripheral blood as a source of transplantable hematopoietic tissue. However, because of the reduced volume, the stem cell content is limited; therefore its use as a graft for adult patients might require ex vivo manipulations. Two systems have been described that identify these stem cell populations in vitro in both mice and humans: (1) the long-term culture-initiating cells (LTC-IC), thus named because of their ability to support the growth of hematopoietic colonies (colony-forming cell (CFC)) for 5-6 weeks when co-cultured on stromal layers; (2) the generation of hematopoietic progenitors (CFC) from stroma-free liquid cultures for extended periods of time, which provides further indirect evidence of the presence of primitive stem cells. Both systems detect largely overlapping but not identical populations of stem cells. Thus the identification of the growth factor requirements for the maintenance and amplification of both systems is relevant. On this basis, analysis of the effects of 18 cytokine combinations on stroma-free liquid cultures of CB CD34+ cells, showed that: (1) after 7- and 14 day-incubation periods, several growth factor combinations expanded the LTC-IC pool to a similar extent; as compared to the LTC-IC, the generation of CFC was not impressive; (2) time-course analysis of the LTC-IC expansion demonstrated that, by extending the incubation period, only a few growth factor combinations, containing FL, TPO, KL and IL6, could support a further, increasingly greater LTC-IC expansion (up to 270000-fold of the initial value). In similar culture conditions, CFC production underwent continuous expansion, which persisted for over 7 months and reached values of one million-fold of the initial value. The simultaneous presence of FL and TPO was both necessary and sufficient to support this phenomenon. The addition of KL+/-IL6 did not appear to substantially modify the extent of LTC-IC expansion; nevertheless, it played an important role in sustaining an even more massive and prolonged output of CFU-GM, CFU-Mk and BFU/CFU-GEMM (up to 100 million-fold); (3) the presence of IL3 was found to be negative, in that it inhibited both the extent of LTC-IC expansion and the long-term generation of CFC. Thus, FL and TPO appear as two unique growth factors that preferentially support the self-renewal of primitive stem cells; the additional presence of KL and IL6 seems to enhance the proliferative potential of at least one subpopulation of daughter stem cells, which may follow three differentiation pathways. Far from being definitive, our data demonstrated that massive stem cell expansion, in cord blood, can be obtained in reasonably well-defined culture conditions. This could represent an initial step towards larger scale cultures for transplantation and gene therapy protocols.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593270     DOI: 10.1038/sj.leu.2401003

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  16 in total

1.  Ex vivo expansion of human umbilical cord blood CD34+ cells in a collagen bead-containing 3-dimensional culture system.

Authors:  Han-Soo Kim; Jong Baeck Lim; Yoo Hong Min; Seung Tae Lee; Chuhl Joo Lyu; Eun Seok Kim; Hyun Ok Kim
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

2.  The comparison of different protocols for expansion of umbilical-cord blood hematopoietic stem cells.

Authors:  Mihaela Chivu; Carmen C Diaconu; Coralia Bleotu; Irina Alexiu; Lorelei Brasoveanu; C Cernescu
Journal:  J Cell Mol Med       Date:  2004 Apr-Jun       Impact factor: 5.310

3.  Oct-4A isoform is expressed in human cord blood-derived CD133 stem cells and differentiated progeny.

Authors:  M Howe; J Zhao; Y Bodenburg; C P McGuckin; N Forraz; R G Tilton; R J Urban; L Denner
Journal:  Cell Prolif       Date:  2009-03-25       Impact factor: 6.831

4.  Expansion of human hematopoietic stem cells for transplantation: trends and perspectives.

Authors:  Hera Andrade-Zaldívar; Leticia Santos; Antonio De León Rodríguez
Journal:  Cytotechnology       Date:  2008-03-29       Impact factor: 2.058

5.  What is the future for cord blood stem cells?

Authors:  E A de Wynter
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

Review 6.  Engineering cord blood to improve engraftment after cord blood transplant.

Authors:  Rohtesh S Mehta; Hema Dave; Catherine M Bollard; Elizabeth J Shpall
Journal:  Stem Cell Investig       Date:  2017-05-25

7.  Overcoming the barriers to umbilical cord blood transplantation.

Authors:  Susan Staba Kelly; Simrit Parmar; Marcos De Lima; Simon Robinson; Elizabeth Shpall
Journal:  Cytotherapy       Date:  2010-04       Impact factor: 5.414

8.  Ex vivo mimicry of normal and abnormal human hematopoiesis.

Authors:  Teresa Mortera-Blanco; Maria Rende; Hugo Macedo; Serene Farah; Alexander Bismarck; Athanasios Mantalaris; Nicki Panoskaltsis
Journal:  J Vis Exp       Date:  2012-04-10       Impact factor: 1.355

9.  ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by interfering with the Stat5b pathway.

Authors:  Tatiana Vignudelli; Tommaso Selmi; Andrea Martello; Sandra Parenti; Alexis Grande; Claudia Gemelli; Tommaso Zanocco-Marani; Sergio Ferrari
Journal:  Mol Biol Cell       Date:  2010-08-11       Impact factor: 4.138

10.  Stem cells expressing homing receptors could be expanded from cryopreserved and unselected cord blood.

Authors:  Young-Ho Lee; Jin-Yeong Han; Su-Yeong Seo; Kyeong-Hee Kim; Young-Ah Lee; Young-Seok Lee; Hyung-Sik Lee; Won-Joo Hur; Hun Han; Hyuk-Chan Kwon; Jae-Seok Kim; Hyo-Jin Kim
Journal:  J Korean Med Sci       Date:  2004-10       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.